1 Market Overview of Selective Cox-2 Inhibitors 1.1 Selective Cox-2 Inhibitors Market Overview 1.1.1 Selective Cox-2 Inhibitors Product Scope 1.1.2 Selective Cox-2 Inhibitors Market Status and Outlook 1.2 Global Selective Cox-2 Inhibitors Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global Selective Cox-2 Inhibitors Market Size by Region (2016-2027) 1.4 Global Selective Cox-2 Inhibitors Historic Market Size by Region (2016-2021) 1.5 Global Selective Cox-2 Inhibitors Market Size Forecast by Region (2022-2027) 1.6 Key Regions, Selective Cox-2 Inhibitors Market Size (2016-2027) 1.6.1 North America Selective Cox-2 Inhibitors Market Size (2016-2027) 1.6.2 Europe Selective Cox-2 Inhibitors Market Size (2016-2027) 1.6.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2016-2027) 1.6.4 Latin America Selective Cox-2 Inhibitors Market Size (2016-2027) 1.6.5 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2016-2027) 2 Selective Cox-2 Inhibitors Market Overview by Type 2.1 Global Selective Cox-2 Inhibitors Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2016-2021) 2.3 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2022-2027) 2.4 Meloxicam 2.5 Celecoxib 2.6 Etoricoxib 2.7 Imrecoxib 2.8 Etodolac 2.9 Parecoxib 2.10 Other 3 Selective Cox-2 Inhibitors Market Overview by Application 3.1 Global Selective Cox-2 Inhibitors Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2016-2021) 3.3 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2022-2027) 3.4 Rheumatoid Arthritis 3.5 Osteoarthritis 3.6 Spondylosis Chronica Ankylopoietica 3.7 Other 4 Selective Cox-2 Inhibitors Competition Analysis by Players 4.1 Global Selective Cox-2 Inhibitors Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2020) 4.3 Date of Key Players Enter into Selective Cox-2 Inhibitors Market 4.4 Global Top Players Selective Cox-2 Inhibitors Headquarters and Area Served 4.5 Key Players Selective Cox-2 Inhibitors Product Solution and Service 4.6 Competitive Status 4.6.1 Selective Cox-2 Inhibitors Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Boehringer-Ingelheim 5.1.1 Boehringer-Ingelheim Profile 5.1.2 Boehringer-Ingelheim Main Business 5.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Products, Services and Solutions 5.1.4 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.1.5 Boehringer-Ingelheim Recent Developments 5.2 TerSera Therapeutics 5.2.1 TerSera Therapeutics Profile 5.2.2 TerSera Therapeutics Main Business 5.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Products, Services and Solutions 5.2.4 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.2.5 TerSera Therapeutics Recent Developments 5.3 Iroko Pharmaceuticals 5.5.1 Iroko Pharmaceuticals Profile 5.3.2 Iroko Pharmaceuticals Main Business 5.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions 5.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.3.5 Apotex Recent Developments 5.4 Apotex 5.4.1 Apotex Profile 5.4.2 Apotex Main Business 5.4.3 Apotex Selective Cox-2 Inhibitors Products, Services and Solutions 5.4.4 Apotex Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.4.5 Apotex Recent Developments 5.5 Yung Shin Pharmaceutical 5.5.1 Yung Shin Pharmaceutical Profile 5.5.2 Yung Shin Pharmaceutical Main Business 5.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions 5.5.4 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.5.5 Yung Shin Pharmaceutical Recent Developments 5.6 Breckenridge Pharmaceutical 5.6.1 Breckenridge Pharmaceutical Profile 5.6.2 Breckenridge Pharmaceutical Main Business 5.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions 5.6.4 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.6.5 Breckenridge Pharmaceutical Recent Developments 5.7 Meda Pharmaceuticals 5.7.1 Meda Pharmaceuticals Profile 5.7.2 Meda Pharmaceuticals Main Business 5.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions 5.7.4 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.7.5 Meda Pharmaceuticals Recent Developments 5.8 Cipla 5.8.1 Cipla Profile 5.8.2 Cipla Main Business 5.8.3 Cipla Selective Cox-2 Inhibitors Products, Services and Solutions 5.8.4 Cipla Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.8.5 Cipla Recent Developments 5.9 Glenmark Pharmaceuticals 5.9.1 Glenmark Pharmaceuticals Profile 5.9.2 Glenmark Pharmaceuticals Main Business 5.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions 5.9.4 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.9.5 Glenmark Pharmaceuticals Recent Developments 5.10 Teva 5.10.1 Teva Profile 5.10.2 Teva Main Business 5.10.3 Teva Selective Cox-2 Inhibitors Products, Services and Solutions 5.10.4 Teva Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.10.5 Teva Recent Developments 5.11 PuraCap Pharmaceutical 5.11.1 PuraCap Pharmaceutical Profile 5.11.2 PuraCap Pharmaceutical Main Business 5.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions 5.11.4 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.11.5 PuraCap Pharmaceutical Recent Developments 5.12 Almirall Limited 5.12.1 Almirall Limited Profile 5.12.2 Almirall Limited Main Business 5.12.3 Almirall Limited Selective Cox-2 Inhibitors Products, Services and Solutions 5.12.4 Almirall Limited Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.12.5 Almirall Limited Recent Developments 5.13 Lupin Pharmaceuticals 5.13.1 Lupin Pharmaceuticals Profile 5.13.2 Lupin Pharmaceuticals Main Business 5.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions 5.13.4 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.13.5 Lupin Pharmaceuticals Recent Developments 5.14 Aurobindo Pharma 5.14.1 Aurobindo Pharma Profile 5.14.2 Aurobindo Pharma Main Business 5.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Products, Services and Solutions 5.14.4 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.14.5 Aurobindo Pharma Recent Developments 5.15 Pfizer 5.15.1 Pfizer Profile 5.15.2 Pfizer Main Business 5.15.3 Pfizer Selective Cox-2 Inhibitors Products, Services and Solutions 5.15.4 Pfizer Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.15.5 Pfizer Recent Developments 5.16 Mylan 5.16.1 Mylan Profile 5.16.2 Mylan Main Business 5.16.3 Mylan Selective Cox-2 Inhibitors Products, Services and Solutions 5.16.4 Mylan Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.16.5 Mylan Recent Developments 5.17 Takeda 5.17.1 Takeda Profile 5.17.2 Takeda Main Business 5.17.3 Takeda Selective Cox-2 Inhibitors Products, Services and Solutions 5.17.4 Takeda Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.17.5 Takeda Recent Developments 5.18 Bayer 5.18.1 Bayer Profile 5.18.2 Bayer Main Business 5.18.3 Bayer Selective Cox-2 Inhibitors Products, Services and Solutions 5.18.4 Bayer Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.18.5 Bayer Recent Developments 5.19 Novacap 5.19.1 Novacap Profile 5.19.2 Novacap Main Business 5.19.3 Novacap Selective Cox-2 Inhibitors Products, Services and Solutions 5.19.4 Novacap Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.19.5 Novacap Recent Developments 5.20 Abbott 5.20.1 Abbott Profile 5.20.2 Abbott Main Business 5.20.3 Abbott Selective Cox-2 Inhibitors Products, Services and Solutions 5.20.4 Abbott Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.20.5 Abbott Recent Developments 5.21 Geri-Care 5.21.1 Geri-Care Profile 5.21.2 Geri-Care Main Business 5.21.3 Geri-Care Selective Cox-2 Inhibitors Products, Services and Solutions 5.21.4 Geri-Care Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.21.5 Geri-Care Recent Developments 5.22 Perrigo 5.22.1 Perrigo Profile 5.22.2 Perrigo Main Business 5.22.3 Perrigo Selective Cox-2 Inhibitors Products, Services and Solutions 5.22.4 Perrigo Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.22.5 Perrigo Recent Developments 5.23 Kopran 5.23.1 Kopran Profile 5.23.2 Kopran Main Business 5.23.3 Kopran Selective Cox-2 Inhibitors Products, Services and Solutions 5.23.4 Kopran Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.23.5 Kopran Recent Developments 5.24 Merck 5.24.1 Merck Profile 5.24.2 Merck Main Business 5.24.3 Merck Selective Cox-2 Inhibitors Products, Services and Solutions 5.24.4 Merck Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.24.5 Merck Recent Developments 5.25 Hengrui pharmaceutical 5.25.1 Hengrui pharmaceutical Profile 5.25.2 Hengrui pharmaceutical Main Business 5.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions 5.25.4 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.25.5 Hengrui pharmaceutical Recent Developments 5.26 Kelun Group 5.26.1 Kelun Group Profile 5.26.2 Kelun Group Main Business 5.26.3 Kelun Group Selective Cox-2 Inhibitors Products, Services and Solutions 5.26.4 Kelun Group Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.26.5 Kelun Group Recent Developments 5.27 Qilu Pharmaceutical 5.27.1 Qilu Pharmaceutical Profile 5.27.2 Qilu Pharmaceutical Main Business 5.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions 5.27.4 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.27.5 Qilu Pharmaceutical Recent Developments 5.28 Taro Pharmaceuticals  5.28.1 Taro Pharmaceuticals  Profile 5.28.2 Taro Pharmaceuticals  Main Business 5.28.3 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Products, Services and Solutions 5.28.4 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Revenue (US$ Million) & (2016-2021) 5.28.5 Taro Pharmaceuticals  Recent Developments 6 North America 6.1 North America Selective Cox-2 Inhibitors Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Selective Cox-2 Inhibitors Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Selective Cox-2 Inhibitors Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Selective Cox-2 Inhibitors Market Dynamics 11.1 Selective Cox-2 Inhibitors Industry Trends 11.2 Selective Cox-2 Inhibitors Market Drivers 11.3 Selective Cox-2 Inhibitors Market Challenges 11.4 Selective Cox-2 Inhibitors Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market Selective Cox-2 Inhibitors Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global Selective Cox-2 Inhibitors Market Size by Region (2016-2021) & (US$ Million) Table 3. Global Selective Cox-2 Inhibitors Market Size Share by Region (2016-2021) Table 4. Global Selective Cox-2 Inhibitors Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global Selective Cox-2 Inhibitors Forecasted Market Size Share by Region (2022-2027) Table 6. Global Selective Cox-2 Inhibitors Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global Selective Cox-2 Inhibitors Market Size by Type (2016-2021) & (US$ Million) Table 8. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2016-2021) Table 9. Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2022-2027) Table 11. Global Selective Cox-2 Inhibitors Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global Selective Cox-2 Inhibitors Market Size by Application (2016-2021) & (US$ Million) Table 13. Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2016-2021) Table 14. Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2022-2027) Table 16. Global Selective Cox-2 Inhibitors Revenue (US$ Million) by Players (2016-2021) Table 17. Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2020) Table 19. Date of Key Manufacturers Enter into Selective Cox-2 Inhibitors Market Table 20. Global Selective Cox-2 Inhibitors Top Players Headquarters and Area Served Table 21. Selective Cox-2 Inhibitors Product Solution and Service Table 22. Global Selective Cox-2 Inhibitors Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Boehringer-Ingelheim Basic Information List Table 25. Boehringer-Ingelheim Description and Business Overview Table 26. Boehringer-Ingelheim Selective Cox-2 Inhibitors Products, Services and Solutions Table 27. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Boehringer-Ingelheim (2016-2021) Table 28. Boehringer-Ingelheim Recent Developments Table 29. TerSera Therapeutics Basic Information List Table 30. TerSera Therapeutics Description and Business Overview Table 31. TerSera Therapeutics Selective Cox-2 Inhibitors Products, Services and Solutions Table 32. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of TerSera Therapeutics (2016-2021) Table 33. TerSera Therapeutics Recent Developments Table 34. Iroko Pharmaceuticals Basic Information List Table 35. Iroko Pharmaceuticals Description and Business Overview Table 36. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions Table 37. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Iroko Pharmaceuticals (2016-2021) Table 38. Iroko Pharmaceuticals Recent Developments Table 39. Apotex Basic Information List Table 40. Apotex Description and Business Overview Table 41. Apotex Selective Cox-2 Inhibitors Products, Services and Solutions Table 42. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Apotex (2016-2021) Table 43. Apotex Recent Developments Table 44. Yung Shin Pharmaceutical Basic Information List Table 45. Yung Shin Pharmaceutical Description and Business Overview Table 46. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions Table 47. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Yung Shin Pharmaceutical (2016-2021) Table 48. Yung Shin Pharmaceutical Recent Developments Table 49. Breckenridge Pharmaceutical Basic Information List Table 50. Breckenridge Pharmaceutical Description and Business Overview Table 51. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions Table 52. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Breckenridge Pharmaceutical (2016-2021) Table 53. Breckenridge Pharmaceutical Recent Developments Table 54. Meda Pharmaceuticals Basic Information List Table 55. Meda Pharmaceuticals Description and Business Overview Table 56. Meda Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions Table 57. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Meda Pharmaceuticals (2016-2021) Table 58. Meda Pharmaceuticals Recent Developments Table 59. Cipla Basic Information List Table 60. Cipla Description and Business Overview Table 61. Cipla Selective Cox-2 Inhibitors Products, Services and Solutions Table 62. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Cipla (2016-2021) Table 63. Cipla Recent Developments Table 64. Glenmark Pharmaceuticals Basic Information List Table 65. Glenmark Pharmaceuticals Description and Business Overview Table 66. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions Table 67. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Glenmark Pharmaceuticals (2016-2021) Table 68. Glenmark Pharmaceuticals Recent Developments Table 69. Teva Basic Information List Table 70. Teva Description and Business Overview Table 71. Teva Selective Cox-2 Inhibitors Products, Services and Solutions Table 72. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Teva (2016-2021) Table 73. Teva Recent Developments Table 74. PuraCap Pharmaceutical Basic Information List Table 75. PuraCap Pharmaceutical Description and Business Overview Table 76. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions Table 77. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of PuraCap Pharmaceutical (2016-2021) Table 78. PuraCap Pharmaceutical Recent Developments Table 79. Almirall Limited Basic Information List Table 80. Almirall Limited Description and Business Overview Table 81. Almirall Limited Selective Cox-2 Inhibitors Products, Services and Solutions Table 82. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Almirall Limited (2016-2021) Table 83. Almirall Limited Recent Developments Table 84. Lupin Pharmaceuticals Basic Information List Table 85. Lupin Pharmaceuticals Description and Business Overview Table 86. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Products, Services and Solutions Table 87. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Lupin Pharmaceuticals (2016-2021) Table 88. Lupin Pharmaceuticals Recent Developments Table 89. Aurobindo Pharma Basic Information List Table 90. Aurobindo Pharma Description and Business Overview Table 91. Aurobindo Pharma Selective Cox-2 Inhibitors Products, Services and Solutions Table 92. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Aurobindo Pharma (2016-2021) Table 93. Aurobindo Pharma Recent Developments Table 94. Pfizer Basic Information List Table 95. Pfizer Description and Business Overview Table 96. Pfizer Selective Cox-2 Inhibitors Products, Services and Solutions Table 97. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Pfizer (2016-2021) Table 98. Pfizer Recent Developments Table 99. Mylan Basic Information List Table 100. Mylan Description and Business Overview Table 101. Mylan Selective Cox-2 Inhibitors Products, Services and Solutions Table 102. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Mylan (2016-2021) Table 103. Mylan Recent Developments Table 104. Takeda Basic Information List Table 105. Takeda Description and Business Overview Table 106. Takeda Selective Cox-2 Inhibitors Products, Services and Solutions Table 107. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Takeda (2016-2021) Table 108. Takeda Recent Developments Table 109. Bayer Basic Information List Table 110. Bayer Description and Business Overview Table 111. Bayer Selective Cox-2 Inhibitors Products, Services and Solutions Table 112. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Bayer (2016-2021) Table 113. Bayer Recent Developments Table 114. Novacap Basic Information List Table 115. Novacap Description and Business Overview Table 116. Novacap Selective Cox-2 Inhibitors Products, Services and Solutions Table 117. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Novacap (2016-2021) Table 118. Novacap Recent Developments Table 119. Abbott Basic Information List Table 120. Abbott Description and Business Overview Table 121. Abbott Selective Cox-2 Inhibitors Products, Services and Solutions Table 122. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Abbott (2016-2021) Table 123. Abbott Recent Developments Table 124. Geri-Care Basic Information List Table 125. Geri-Care Description and Business Overview Table 126. Geri-Care Selective Cox-2 Inhibitors Products, Services and Solutions Table 127. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Geri-Care (2016-2021) Table 128. Geri-Care Recent Developments Table 129. Perrigo Basic Information List Table 130. Perrigo Description and Business Overview Table 131. Perrigo Selective Cox-2 Inhibitors Products, Services and Solutions Table 132. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Perrigo (2016-2021) Table 133. Perrigo Recent Developments Table 134. Kopran Basic Information List Table 135. Kopran Description and Business Overview Table 136. Kopran Selective Cox-2 Inhibitors Products, Services and Solutions Table 137. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Kopran (2016-2021) Table 138. Kopran Recent Developments Table 139. Merck Basic Information List Table 140. Merck Description and Business Overview Table 141. Merck Selective Cox-2 Inhibitors Products, Services and Solutions Table 142. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Merck (2016-2021) Table 143. Merck Recent Developments Table 144. Hengrui pharmaceutical Basic Information List Table 145. Hengrui pharmaceutical Description and Business Overview Table 146. Hengrui pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions Table 147. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Hengrui pharmaceutical (2016-2021) Table 148. Hengrui pharmaceutical Recent Developments Table 149. Kelun Group Basic Information List Table 150. Kelun Group Description and Business Overview Table 151. Kelun Group Selective Cox-2 Inhibitors Products, Services and Solutions Table 152. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Kelun Group (2016-2021) Table 153. Kelun Group Recent Developments Table 154. Qilu Pharmaceutical Basic Information List Table 155. Qilu Pharmaceutical Description and Business Overview Table 156. Qilu Pharmaceutical Selective Cox-2 Inhibitors Products, Services and Solutions Table 157. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Qilu Pharmaceutical (2016-2021) Table 158. Qilu Pharmaceutical Recent Developments Table 159. Taro Pharmaceuticals  Basic Information List Table 160. Taro Pharmaceuticals  Description and Business Overview Table 161. Taro Pharmaceuticals  Selective Cox-2 Inhibitors Products, Services and Solutions Table 162. Revenue (US$ Million) in Selective Cox-2 Inhibitors Business of Taro Pharmaceuticals  (2016-2021) Table 163. Taro Pharmaceuticals  Recent Developments Table 164. North America Selective Cox-2 Inhibitors Market Size by Country (2016-2021) & (US$ Million) Table 165. North America Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) Table 166. Europe Selective Cox-2 Inhibitors Market Size by Country (2016-2021) & (US$ Million) Table 167. Europe Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) Table 168. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2016-2021) & (US$ Million) Table 169. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2022-2027) & (US$ Million) Table 170. Asia-Pacific Selective Cox-2 Inhibitors Market Share by Region (2016-2021) Table 171. Asia-Pacific Selective Cox-2 Inhibitors Market Share by Region (2022-2027) Table 172. Latin America Selective Cox-2 Inhibitors Market Size by Country (2016-2021) & (US$ Million) Table 173. Latin America Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) Table 174. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Players (2016-2021) & (US$ Million) Table 175. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) Table 176. Selective Cox-2 Inhibitors Market Trends Table 177. Selective Cox-2 Inhibitors Market Drivers Table 178. Selective Cox-2 Inhibitors Market Challenges Table 179. Selective Cox-2 Inhibitors Market Restraints Table 180. Research Programs/Design for This Report Table 181. Key Data Information from Secondary Sources Table 182. Key Data Information from Primary Sources List of Figures Figure 1. Global Selective Cox-2 Inhibitors Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global Selective Cox-2 Inhibitors Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global Selective Cox-2 Inhibitors Market Share by Regions: 2021 VS 2027 Figure 4. Global Selective Cox-2 Inhibitors Forecasted Market Size Share by Region (2022-2027) Figure 5. North America Selective Cox-2 Inhibitors Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe Selective Cox-2 Inhibitors Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific Selective Cox-2 Inhibitors Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America Selective Cox-2 Inhibitors Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa Selective Cox-2 Inhibitors Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global Selective Cox-2 Inhibitors Market Size Share by Type in 2021 & 2027 Figure 11. Meloxicam Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Celecoxib Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Etoricoxib Market Size (US$ Million) YoY Growth (2016-2027) Figure 14. Imrecoxib Market Size (US$ Million) YoY Growth (2016-2027) Figure 15. Etodolac Market Size (US$ Million) YoY Growth (2016-2027) Figure 16. Parecoxib Market Size (US$ Million) YoY Growth (2016-2027) Figure 17. Global Selective Cox-2 Inhibitors Market Size Share by Application in 2021 & 2027 Figure 18. Rheumatoid Arthritis Market Size (US$ Million) YoY Growth (2016-2027) Figure 19. Osteoarthritis Market Size (US$ Million) YoY Growth (2016-2027) Figure 20. Spondylosis Chronica Ankylopoietica Market Size (US$ Million) YoY Growth (2016-2027) Figure 21. Other Market Size (US$ Million) YoY Growth (2016-2027) Figure 22. Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 23. Global Top 5 and Top 10 Players Selective Cox-2 Inhibitors Market Share in 2020 Figure 24. North America Selective Cox-2 Inhibitors Market Share by Country (2016-2027) Figure 25. United States Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 26. Canada Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 27. Germany Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 28. France Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 29. U.K. Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 30. Italy Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 31. Russia Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 32. Nordic Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 33. Rest of Europe Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 34. Asia-Pacific Selective Cox-2 Inhibitors Market Share by Region (2016-2027) Figure 35. China Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 36. Japan Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 37. South Korea Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 38. Southeast Asia Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 39. India Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 40. Australia Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 41. Rest of Asia-Pacific Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 42. Latin America Selective Cox-2 Inhibitors Market Share by Country (2016-2027) Figure 43. Mexico Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 44. Brazil Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 45. Rest of Latin America Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 46. Middle East & Africa Selective Cox-2 Inhibitors Market Share by Country (2016-2027) Figure 47. Turkey Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 48. Saudi Arabia Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 49. UAE Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 50. Rest of Middle East & Africa Selective Cox-2 Inhibitors Market Size (2016-2027) & (US$ Million) Figure 51. Bottom-up and Top-down Approaches for This Report Figure 52. Data Triangulation

Boehringer-Ingelheim TerSera Therapeutics Iroko Pharmaceuticals Apotex Yung Shin Pharmaceutical Breckenridge Pharmaceutical Meda Pharmaceuticals Cipla Glenmark Pharmaceuticals Teva PuraCap Pharmaceutical Almirall Limited Lupin Pharmaceuticals Aurobindo Pharma Pfizer Mylan Takeda Bayer Novacap Abbott Geri-Care Perrigo Kopran Merck Hengrui pharmaceutical Kelun Group Qilu Pharmaceutical Taro Pharmaceuticals